Humira Biosimilar Global Market Report 2025

Description

A Humira biosimilar is a biologic drug developed to closely replicate Humira in the treatment of autoimmune disorders. It mirrors the original in terms of safety, effectiveness, and quality but is generally more affordable. By offering a cost-effective alternative, these biosimilars improve patient access to treatment while helping to reduce overall healthcare expenses.

The primary product types of Humira biosimilars include adalimumab biosimilars and others. Adalimumab biosimilars are biologic medications that closely resemble the reference anti-TNF drug Humira, offering equivalent safety, effectiveness, and quality in the treatment of autoimmune conditions. These biosimilars are distributed through various channels such as hospital pharmacies, retail pharmacies, online pharmacies, and others, and are used for a range of conditions including rheumatoid arthritis, psoriasis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, and more.

The humira biosimilars market research report is one of a series of new reports from The Business Research Company that provides humira biosimilars market statistics, including the humira biosimilars industry global market size, regional shares, competitors with the humira biosimilars market share, detailed humira biosimilars market segments, market trends, opportunities, and any further data you may need to thrive in the humira biosimilars industry. This humira biosimilars market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The humira biosimilar market size has grown rapidly in recent years. It will grow from $3.28 billion in 2024 to $3.70 billion in 2025 at a compound annual growth rate (CAGR) of 13.0%. The growth observed during the historic period can be attributed to the increasing demand for cost-effective alternatives, rising approval of biosimilars by regulatory bodies, the growing prevalence of autoimmune diseases, expanding healthcare access in emerging markets, and the high cost of original biologic drugs.

The humira biosimilar market size is expected to see rapid growth in the next few years. It will grow to $5.96 billion in 2029 at a compound annual growth rate (CAGR) of 12.6%. Looking ahead, growth in the forecast period is expected to be driven by advancements in biosimilar development technologies, increasing efforts to contain healthcare costs, the expiration of patents for original biologics, improvements in market access and reimbursement policies, and the rising adoption of biosimilars in oncology and autoimmune diseases. Key trends expected during this period include the increasing approval of additional biosimilars, advancements in manufacturing technologies, expanding research and development activities, the development and approval of new biosimilar drugs, and innovations in drug formulations.

The growing prevalence of autoimmune diseases is expected to drive the expansion of the Humira biosimilar market. Autoimmune diseases arise when the immune system mistakenly attacks healthy cells, tissues, or organs. This rise in cases is increasingly linked to environmental pollution, which can disrupt immune system function and elevate the risk of autoimmune reactions. Humira biosimilars function by blocking tumor necrosis factor (TNF), a protein responsible for causing inflammation in autoimmune conditions. By inhibiting TNF, these biosimilars help reduce the immune system's overactivity, relieve symptoms, and prevent damage to healthy tissue. For instance, in June 2024, the Australian Institute of Health and Welfare reported that an estimated 514,000 Australians (2.0% of the population) were living with rheumatoid arthritis in 2022, including 2.5% of females and 1.6% of males. As a result, the rising incidence of autoimmune diseases is boosting demand for Humira biosimilars.

Key players in the Humira biosimilar market are focused on advancing cost-effective TNF-blocking therapies to improve treatment accessibility for autoimmune diseases. TNF blockers are biologic medications that inhibit the action of TNF, reducing inflammation and disease symptoms. For example, in July 2023, Organon & Co., a U.S.-based pharmaceutical company, partnered with Samsung Bioepis, a South Korea-based biotech firm, to launch HADLIMA, a Humira biosimilar. HADLIMA is available in both citrate-free high-concentration (100 mg/mL) and citrate-containing low-concentration (50 mg/mL) formulations, mirroring the original Humira options. It is offered at a price approximately 85% lower than the originator's list price and is supported by patient assistance programs. This launch, permitted by a global settlement, significantly enhances affordability and access to autoimmune treatments in the U.S.

In February 2024, Alvotech, a Luxembourg-based biotech company, partnered with Teva Pharmaceuticals to introduce SIMLANDI, the first high-concentration, citrate-free interchangeable Humira biosimilar in the U.S. The collaboration aims to expand access to affordable adalimumab therapy, stimulate biosimilar market competition, and improve treatment outcomes for patients with chronic autoimmune diseases. Teva Pharmaceuticals is a U.S.-based pharmaceutical company.

Major players in the humira biosimilar market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., LG Chem Ltd., Amgen Inc., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim GmbH, Mylan N.V., Sandoz Group AG, Fresenius Kabi AG, Celltrion Inc., Biocon Limited, Torrent Pharmaceuticals, Samsung Bioepis Co. Ltd., Alvotech, Coherus BioSciences Inc., Zydus Cadila, Hetero Drugs Ltd., Fujifilm Kyowa Kirin Biologics, Synermore Biologics, and CVS Health.

North America was the largest region in the humira biosimilar market in 2024. The regions covered in humira biosimilar report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the humira biosimilar market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The humira biosimilar market consists of sales of prefilled syringes, autoinjector (AI) pens, and vials. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Humira Biosimilar Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on humira biosimilar market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for humira biosimilar ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The humira biosimilar market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Product Type: Adalimumab Biosimilars; Other Types
2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Other Distribution Channels
3) By Application: Rheumatoid Arthritis; Psoriasis; Crohn's Disease; Ulcerative Colitis; Ankylosing Spondylitis; Other Applications
Subsegments:
1) By Adalimumab Biosimilars: Fully Human Monoclonal Antibodies; Fragment Crystallizable (Fc) Region Modified Biosimilars; High-Concentration Formulations; Citrate-Free Formulations
2) By Other Types: Biosimilars Of Other Tumor Necrosis Factor (TNF) Inhibitors; Interchangeable Biosimilars; Pegylated Biosimilars; Non-Adalimumab Monoclonal Antibody Biosimilars
Companies Mentioned: Pfizer Inc.; Merck & Co. Inc.; AbbVie Inc.; LG Chem Ltd.; Amgen Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.

Product Code: r35435

1. Executive Summary

2. Humira Biosimilar Market Characteristics

3. Humira Biosimilar Market Trends And Strategies

4. Humira Biosimilar Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Humira Biosimilar Growth Analysis And Strategic Analysis Framework

5.1. Global Humira Biosimilar PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Humira Biosimilar Market Growth Rate Analysis
5.4. Global Humira Biosimilar Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Humira Biosimilar Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Humira Biosimilar Total Addressable Market (TAM)

6. Humira Biosimilar Market Segmentation

6.1. Global Humira Biosimilar Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Adalimumab Biosimilars
Other Types
6.2. Global Humira Biosimilar Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Other Distribution Channels
6.3. Global Humira Biosimilar Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Rheumatoid Arthritis
Psoriasis
Crohn's Disease
Ulcerative Colitis
Ankylosing Spondylitis
Other Applications
6.4. Global Humira Biosimilar Market, Sub-Segmentation Of Adalimumab Biosimilars, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Fully Human Monoclonal Antibodies
Fragment Crystallizable (Fc) Region Modified Biosimilars
High-Concentration Formulations
Citrate-Free Formulations
6.5. Global Humira Biosimilar Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Biosimilars of Other Tumor Necrosis Factor (TNF) Inhibitors
Interchangeable Biosimilars
Pegylated Biosimilars
Non-Adalimumab Monoclonal Antibody Biosimilars

7. Humira Biosimilar Market Regional And Country Analysis

7.1. Global Humira Biosimilar Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Humira Biosimilar Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Humira Biosimilar Market

8.1. Asia-Pacific Humira Biosimilar Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Humira Biosimilar Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Humira Biosimilar Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Humira Biosimilar Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Humira Biosimilar Market

9.1. China Humira Biosimilar Market Overview
9.2. China Humira Biosimilar Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Humira Biosimilar Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Humira Biosimilar Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Humira Biosimilar Market

10.1. India Humira Biosimilar Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Humira Biosimilar Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Humira Biosimilar Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Humira Biosimilar Market

11.1. Japan Humira Biosimilar Market Overview
11.2. Japan Humira Biosimilar Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Humira Biosimilar Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Humira Biosimilar Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Humira Biosimilar Market

12.1. Australia Humira Biosimilar Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Humira Biosimilar Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Humira Biosimilar Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Humira Biosimilar Market

13.1. Indonesia Humira Biosimilar Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Humira Biosimilar Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Humira Biosimilar Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Humira Biosimilar Market

14.1. South Korea Humira Biosimilar Market Overview
14.2. South Korea Humira Biosimilar Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Humira Biosimilar Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Humira Biosimilar Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Humira Biosimilar Market

15.1. Western Europe Humira Biosimilar Market Overview
15.2. Western Europe Humira Biosimilar Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Humira Biosimilar Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Humira Biosimilar Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Humira Biosimilar Market

16.1. UK Humira Biosimilar Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Humira Biosimilar Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Humira Biosimilar Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Humira Biosimilar Market

17.1. Germany Humira Biosimilar Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Humira Biosimilar Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Humira Biosimilar Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Humira Biosimilar Market

18.1. France Humira Biosimilar Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Humira Biosimilar Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Humira Biosimilar Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Humira Biosimilar Market

19.1. Italy Humira Biosimilar Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Humira Biosimilar Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Humira Biosimilar Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Humira Biosimilar Market

20.1. Spain Humira Biosimilar Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Humira Biosimilar Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Humira Biosimilar Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Humira Biosimilar Market

21.1. Eastern Europe Humira Biosimilar Market Overview
21.2. Eastern Europe Humira Biosimilar Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Humira Biosimilar Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Humira Biosimilar Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Humira Biosimilar Market

22.1. Russia Humira Biosimilar Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Humira Biosimilar Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Humira Biosimilar Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Humira Biosimilar Market

23.1. North America Humira Biosimilar Market Overview
23.2. North America Humira Biosimilar Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Humira Biosimilar Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Humira Biosimilar Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Humira Biosimilar Market

24.1. USA Humira Biosimilar Market Overview
24.2. USA Humira Biosimilar Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Humira Biosimilar Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Humira Biosimilar Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Humira Biosimilar Market

25.1. Canada Humira Biosimilar Market Overview
25.2. Canada Humira Biosimilar Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Humira Biosimilar Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Humira Biosimilar Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Humira Biosimilar Market

26.1. South America Humira Biosimilar Market Overview
26.2. South America Humira Biosimilar Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Humira Biosimilar Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Humira Biosimilar Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Humira Biosimilar Market

27.1. Brazil Humira Biosimilar Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Humira Biosimilar Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Humira Biosimilar Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Humira Biosimilar Market

28.1. Middle East Humira Biosimilar Market Overview
28.2. Middle East Humira Biosimilar Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Humira Biosimilar Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Humira Biosimilar Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Humira Biosimilar Market

29.1. Africa Humira Biosimilar Market Overview
29.2. Africa Humira Biosimilar Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Humira Biosimilar Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Humira Biosimilar Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Humira Biosimilar Market Competitive Landscape And Company Profiles

30.1. Humira Biosimilar Market Competitive Landscape
30.2. Humira Biosimilar Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. LG Chem Ltd. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Humira Biosimilar Market Other Major And Innovative Companies

31.1. Teva Pharmaceutical Industries Ltd.
31.2. Boehringer Ingelheim GmbH
31.3. Mylan N.V.
31.4. Sandoz Group AG
31.5. Fresenius Kabi AG
31.6. Celltrion Inc.
31.7. Biocon Limited
31.8. Torrent Pharmaceuticals
31.9. Samsung Bioepis Co. Ltd.
31.10. Alvotech
31.11. Coherus BioSciences Inc.
31.12. Zydus Cadila
31.13. Hetero Drugs Ltd.
31.14. Fujifilm Kyowa Kirin Biologics
31.15. Synermore Biologics

32. Global Humira Biosimilar Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Humira Biosimilar Market

34. Recent Developments In The Humira Biosimilar Market

35. Humira Biosimilar Market High Potential Countries, Segments and Strategies

35.1 Humira Biosimilar Market In 2029 - Countries Offering Most New Opportunities
35.2 Humira Biosimilar Market In 2029 - Segments Offering Most New Opportunities
35.3 Humira Biosimilar Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer